SCYNEXIS Inc. Common Stock (SCYX)

FairStock Score: 69/100 — STEADY

Key Financials

Strengths

• Generates $3 million in annual free cash flow (5.9% yield on market cap)
• Strong Piotroski F-Score of 7/9 indicating robust financial health across profitability, leverage, and efficiency metrics
• Conservative balance sheet with debt-to-equity of just 0.05, providing financial flexibility
• Superior net profit margin of 60.3% indicating pricing power and operational efficiency
• Revenue growth of 1808.5% demonstrates strong top-line momentum

Concerns

• Altman Z-Score of -4.7 places it in the financial distress zone—elevated bankruptcy risk

AI Analysis

SCYNEXIS Inc. Common Stock is a micro-cap healthcare company valued at $45 million. The business generates $20 million in annual revenue with a 60.3% net margin and $3 million in free cash flow. From a quality standpoint, SCYNEXIS shows solid Piotroski F-Score of 7/9 and distressed Altman Z-Score of -4.7 warrants caution. On valuation, the stock is strong 40.8% free cash flow yield. Growth dynamics show revenue growing at 1808.5% and profit growth of 376.5%. Our composite FairStock Score of 69/100 reflects above-average fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.

Bull Case

SCYNEXIS's 1809% revenue growth trajectory could accelerate as it captures additional market share in the healthcare sector. With $3 million in annual free cash flow (5.9% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.

Bear Case

Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the healthcare space. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer